What kills cancer patients is metastasis, not the primary tumor. Therefore, developing treatments that target metastatic cells is a key objective of the new metastasis inhibitory therapies to increase patient’s chance of long-term survival.
The aim of the present study was to investigate the inhibitory effects of the polyphenol epigallocatechin‑3‑gallate (EGCG) on migration capacity using in vitro-agarose spot assay and microRNAs profiling in MDA-MB-231, MCF-7, HeLa, and HEK-293 cell lines. The migration capacity of cells was significantly reduced. Immunfluorescencestaining showed no effect of EGCG on phospho-Profilin. EGCG upregulated hsa-miR-200a, hsa-miR-146a in MDA-MB-231 without effects on microRNA-124 or its targetgen (alpha –actinin-4) The inhibitory effect of cell migration by treatments with EGCG could not be attributed to lower regulation of EGFR or CD29. These results indicate that EGCG inhibits the migration of breast cancer cells further investigation is needed.